Please login to the form below

Not currently logged in
Email:
Password:

MEDI8897

This page shows the latest MEDI8897 news and features for those working in and with pharma, biotech and healthcare.

US, EU regulators back rapid reviews of AZ’s RSV med

US, EU regulators back rapid reviews of AZ’s RSV med

MEDI8897 is a longer-acting follow-up to AZ’s Synagis (palivizumab), which is currently the only drug approved for preventing RSV in high-risk patients. ... Sanofi paid 120m upfront for a share in MEDI8897 last year with another 495m in development and

Latest news

  • AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

    There’s also provision for up to $470m in sales milestones ties to Synagis, plus a $175m payment due on the US filing for MEDI8897 and another $170m ties to sales ... The Synagis and MEDI8897 deals continues AZ’s policy of focusing firmly on a few

  • Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

    Sanofi is already active in this category after licensing rights to AstraZeneca’s phase II candidate MEDI8897 last year, with both projects aimed at providing treatment for already-established RSV infections.

  • Regeneron drops RSV drug Regeneron drops RSV drug

    The failure of suptavumab to hit the mark in the NURSERY study removes a potential rival for AstraZeneca's RSV candidate MEDI8897 - recently partnered with Sanofi - which is currently in phase

  • Sanofi buys into AZ drug for preventing RSV infections Sanofi buys into AZ drug for preventing RSV infections

    The deal also includes up to 495m in development and sales milestone payments and focuses on MEDI8897, a follow-up to AZ's already-marketed Synagis (palivizumab) which is the first ... MEDI8897 is a fully-human antibody that has an extended half-life in

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur. Joint Development. MEDI8897; monoclonal antibody to respiratory syncytial virus in phase IIb.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Investing in our People
As a small, boutique agency we can and do invest heavily in our team, who produce amazing results for our clients....
Body image and mental health: The psoriasis connection
As part of mental health awareness week, the Mental Health Foundation (MHF) have released a new report on the interaction between body image and mental health. Our Medical Writer Alex...
It’s not the end of the world, is it?
Industry change isn’t always gradual – it can be apocalyptic...

Infographics